Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.
Clinical trial NCT06660511 · RECRUITING
Trial details
- NCT number
- NCT06660511
- Sponsor
- Second Xiangya Hospital of Central South University
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-15
- Primary completion
- 2025-09-01
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.